Shots:

• The P-IIb dose-ranging study evaluates the antiretroviral activity, tolerability & safety of islatravir (0.25/0.75/2.25mg) + doravirine vs DOR/3TC/TDF in a ratio (1:1:1:1) in adults with HIV-1
• The results showed that islatravir + doravirine continued to maintain viral suppression @144wks.; 72.2% of the combined groups had HIV-RNA levels <50 copies/mL similar to 77.4% of DOR/3TC/TDF group.; treatment discontinuations due to drug-related AEs (2.2% & 3.2%) before 48wks. The results were consistent with the 96wks. results in 0.75mg dose group
• Islatravir is currently being evaluated in multiple dosing regimens for HIV-1 as monothx. or in combination with other antiretroviral agents

 ­ Ref: Merck | Image: Merck